SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 10, 2012--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will present
at the 14th annual BIO CEO & Investor Conference at 8:30 a.m.
EST / 5:30 a.m. PST on Tuesday, February 14, 2012, in New York. During
the presentation, Dr. Morrissey will discuss the company’s development
program and plans for cabozantinib, and review the most recent publicly
available data for the compound. He will also provide a general business
update, including the company’s financial outlook for 2012.
The presentation will be webcast and may be accessed in the Event
Calendar page under Investors at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on
cabozantinib (XL184), its most advanced product candidate, in order to
maximize the therapeutic and commercial potential of this compound.
Exelixis believes cabozantinib has the potential to be a high-quality,
broadly-active, differentiated pharmaceutical product that can make a
meaningful difference in the lives of patients. Exelixis has also
established a portfolio of other novel compounds that it believes have
the potential to address serious unmet medical needs, many of which are
being advanced by partners as part of collaborations. For more
information, please visit the company's web site at www.exelixis.com
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Investor
Relations and Corporate Communications
cbutler@exelixis.com
